Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2206 + Endocrine Therapy in HR+ Metastatic Breast Cancer
NCT01240941Phase 2Withdrawn
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Feb 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of MK-2206 in breast cancer, sponsored by Vanderbilt-Ingram Cancer Center. Planned start Feb 2011; status: withdrawn.
02
Drugs
MK-2206
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01240941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01240941.